Introduction
Phenol is a deep chemical peeling (PCP) agent used for removal of fine and coarse facial wrinkling, irregular pigmentation localized to the dermis, and ablation of actinic keratosis. 1 It causes both keratolysis and keratocoagulation, followed by cutaneous regeneration that extends to the reticular dermis. [2] [3] [4] [5] Alongside its skin rejuvenation effect, PCP is associated with a prolonged recovery period and significant bleaching effect. Some of its adverse events include edema, pruritus and exfoliation of skin, photosensitivity, post peel hyperpigmentation, infection, milia, scarring, and long-standing erythema (up to 12 weeks). [5] [6] [7] Achieving a shorter recovery time with lower adverse events rate, especially erythema clearance, will allow a more tolerable and safer treatment.
Hyperbaric oxygen therapy (HBOT) augments tissue oxygen content and thus serves as a primary or adjunctive therapy for a diverse range of medical conditions such as decompression sickness, carbon monoxide poisoning, ischemia, aggressive soft tissue infections, non-healing ulcers, or compromised skin grafts and flaps. [8] [9] [10] [11] [12] [13] We hypothesize that HBOT would accelerate wound healing process and decrease the severity of local skin reactions. Therefore, the purpose of this study was to assess the effect of HBOT on adverse event rate and recovery time following PCP treatment.
Methods

Study Design
A pilot, open-label, randomized controlled clinical study was planned to assess the effect of HBOT on PCP outcome.
Ethical Approval
This clinical study was performed in accordance with the Declaration of Helsinki (1975) and was approved by the institutional review board. Prior to enrollment, participants were informed of the study procedures, possible risks, benefits, and complications. All participants signed an informed consent form. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.
Study Participants
We enrolled healthy, Fitzpatrick skin type 2, non-smoking women, aged 60 to 70 years old, who were candidates for PCP treatment. Participants who had a history of abnormal wound healing, keloid formation, autoimmune disease, or immunodeficiency and under immunosuppressive or systemic steroids or retinoid treatment were excluded. Participants were also excluded if they had received any facial chemical peeling or laser therapy up to 1 year prior to study occurrence.
Randomization
Following PCP treatment, each participant was randomly assigned to either HBOT or control group by opening a sealed envelope with its group allocation.
Hyperbaric Oxygen Therapy Protocol
The study group received 5 consecutive daily hyperbaric treatments, 1 hour long each, at 2 atm (202.65 kPa) with FIO 2 ¼ 1.0 via face mask (held by patients who were instructed not to apply pressure), starting 7 days following PCP due to patient feasibility to attend the session. 14 
Phenol Chemical Peeling Protocol
All chemical peels were performed by a single dermatologist. Prior to treatment, skin type, hue, and indication for peeling were determined.
After each region of the face has been completely covered with the peeling solution (active ingredients phenol 65%, 0.6% croton oil), an occlusive dressing was applied for 24 hours. The occlusive dressing was removed at the next day and bismuth subgallate was applied to the facial skin for a week until reepithelizition. After a week, it was removed using Vaseline (day 7).
Follow-Up and Outcome
All PCP outcomes were assessed using a Likert scale 5-point severity score (5: severe, 4: moderately severe, 3: moderate, 2: mild, 1: none). Participants were asked to self-assess overall improvement of pain, pruritus, erythema, crusting, and scaling separately during days 7 to 14 following PCP.
Standardized digital facial photographs using identical camera (Nikon D60, Tokyo, Japan) and lightning settings were taken during a PCP follow-up examination on days 14 and 35. Photographs were used to assess participants' skin tightness, swelling/edema, erythema, crusting, and scaling by 2 independent investigators (a 20-year experienced dermatologist and a 10-year experienced plastic surgeon, both were unaware to patients' group ascription). All photographs were taken at afternoon hours.
Macroscopic quantification of the skin epithelialization was performed using the computer-assisted image analysis software NIS-Elements Ar (Nikon Instruments Europe BV, Amstelveen, the Netherlands), using a method described previously. 15 All participants filled a 5-item questionnaire on their confidence to appear in public, 14 days following PCP. Each item had a 5-point Likert scale. A summary score was used for analysis, ranges between 5 points (lowest confidence) and 25 points (highest confidence). Adverse events were assessed based on participant's self-report.
Data and Statistical Analysis
Statistical data were calculated by PASW, SPSS version 18 statistical software (IBM, Chicago, IL, USA). Continuous data are expressed as means (standard deviations). Daily patient scores were compared using repeated-measures test. Photographic assessments and public appearance confidence scores were compared using Mann-Whitney U test. Inter-observer agreement was assessed using Spearman r. The level of significance was defined as P < .05.
Results
A total of 8 participants who met the study criteria were enrolled to the study and randomly assigned to HBOT and control groups. Mean age was 62.9 + 4.15 years in both groups (P ¼ .93).
Participants Self-Assessment Comparison
No differences in mean severity scores between the HBOT and control groups for all categories were observed prior to HBOT (see Table 1 , day 7 column). The mean severity scores of erythema and pruritus were lower in the HBOT group than in the control group (mean difference 1.23, P ¼ .015 and 2.125, P ¼ .004, respectively; see Table 1 and Figure 1 ).
Photograph Assessment
Photographic assessment mean severity scores of swelling, erythema, crusting, and scaling 14 days following PCP treatment were lower in the HBOT group (P ¼ .029; see Table 2 ). Percentage of epithelialization at day 14 post PCP treatment was significantly higher in the HBOT group compared to controls (98.5% + 1% vs 94.2% + 1%; P ¼ .021). Correlation coefficients of investigators' inter-observer agreement were 0.77 to 1 for all categories (P < .05). In Figures 2 and 3 , photographs of representative cases from both the HBOT and control groups are shown. 
Appearance in Public Questionnaire
Confidence to appear in public questionnaire scored higher in the HBOT group than controls (20.8 + 1.7 vs 14.5 + 1.3, P ¼ .029).
Adverse Event Report
No other systemic adverse event was reported by participants throughout the entire study and 3 months after the last follow-up examination.
Discussion
The goal of the pilot study was to assess whether HBOT can accelerate wound healing following PCP, as well as decrease the rate and severity of local adverse events and systemic complications. To our knowledge, this is the first study to demonstrate accelerated epithelialization rate and reduction in local adverse reactions following HBOT, as evaluated by both patients and caregivers. In addition, patients treated with HBOT felt more confident about public appearance sooner than controls. Finally, we found that HBOT was safe, well tolerated, and effective among study participants. Hyperbaric oxygen therapy is known to accelerate wound healing through several physiological mechanisms. First, HBOT increases arterial oxygen partial pressure by 40 mm Hg or higher, thus allowing oxygen-dependent collagen matrix formation. 16 Another contribution to oxygen delivery to the wound site is achieved by stimulation of neovascularization by HBOT, either through increased oxygen gradient 17 or through triggering tumor necrosis factor a release. 18 In the cellular level, HBOT contributes to apoptosis attenuation and reduced inflammation through downregulating hypoxia-inducible factor-1a (HIF1a). 19 Increased tissue oxygenation is known to decrease peripheral edema and improve skin viability. 20 Up until now, HBOT was mainly used in the treatment of problematic or chronic wounds such as radiation necrosis and diabetic wounds. As for acute wounds, HBOT was mainly recommended for problematic acute wounds (eg, compromised flaps and grafts). 20 So far, HBOT effect on accelerated healing has been demonstrated in several human and animal studies. 21, 22 In our study, we found increased epithelialization rates in the HBOT group. Together with decreased severity of adverse events following PCP treatment, and although they only received a single treatment about a week later, study results indicate the potential of HBOT to further accelerate wound healing in PCP treatment, if implemented earlier or even before the treatment and performed more than once.
Phenol chemical peeling is used for a variety of indications but is associated with prolonged adverse effects. To date, no clinical study was preformed to evaluate the benefits of HBOT on acute wounds such as those created by PCP. Attempts to minimize the side effects of phenol peel while maintaining its positive effects in previous studies were concentrated on developing various new phenol peeling formulas such as buffered phenol peel, Venner-Kellson, Baker Gordon, Litton, Mee, and Exoderm. 7 Another approach to minimize side effects was the use of different occlusive dressings and powders such as bismuth subgallate. 23 In conclusion, this study innovates by showing that HBOT, in addition to its known benefits in problematic wounds, is also beneficial in accelerating the healing of the non-problematic wound and decreasing the side effects of facial peeling. Our study findings can also be relevant to other laser or chemically based skin resurfacing interventions, providing a faster recovery and milder skin inflammatory reactions compared to standard treatment.
Our pilot study was subject to several limitations such as small sample size not sufficient to assess accurate efficacy and less common adverse events of HBOT. In addition, study participants share a relatively narrow age span and the same Fitzpatrick skin type, and thus, we cannot apply our conclusions to other age and skin type groups.
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